Phase I Clinical Study of MPDL3280A in Patients with Advanced Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222162

Enrollment

Registered

2013-07-29

Start date

2013-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

Interventions

investigational material(s) Generic name etc : Atezolizumab INN of investigational material : atezolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investig

10 mg/kg, 20 mg/kg control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : -

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ECOG Performance Status of 0 or 1 - Histologically or cytologically documented solid tumors - Advanced or recurrent cancer that is refractory to the standard of care or for which no standard of care exists

Exclusion criteria

Exclusion criteria: - Primary central nervous system (CNS) malignancy or symptomatic CNS metastases - Previous or concurrent autoimmune disorder - History of treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies, or cancer vaccine

Design outcomes

Primary

Measure	Time frame
safety CTCAE ver4.03	—

Secondary

Measure	Time frame
efficacy pharmacokinetics RECIST ver1.1, etc.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026